Mucosal and Systemic Immune Responses to Mycobacterium tuberculosis Antigen 85A following Its Co-Delivery with CpG, MPLA or LTB to the Lungs in Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Todoroff, Julie ^a   Lemaire, Muriel M ^b,c   Fillee, Catherine ^d   Jurion, Fabienne ^c   Renauld, Jean Christophe ^b,c   Huygen, Kris ^e   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; GERBU ADJUVANT; HEAT LABILE ESCHERICHIA COLI ENTEROTOXIN SUBUNIT B; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS IMMUNODOMINANT MYCOLYL TRANSFERASE ANTIGEN 85A; PHOSPHORYL LIPID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; CD4+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; LUNG LAVAGE; LUNG TUBERCULOSIS; MONONUCLEAR CELL; MONOTHERAPY; MOUSE; MUCOSAL IMMUNITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; PULMONARY VACCINATION; SPLEEN CELL; SYSTEMIC IMMUNE RESPONSE; VACCINATION;

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; INFLAMMATION; LIPID A; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84877586558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063344     Document Type: Article

References (42)

1. World Health Organization (2010) Tuberculosis- Fact sheet n°104.
2. Roche PW, Triccas JA, Winter N, (1995) BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol 3: 397-401.
3. World Health Organization (2006) The Stop TB Strategy.
4. Stop TB Partnership (2009) Tuberculosis vaccine candidates.
5. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2011) Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 203: 1832-1843.
6. Elamin AA, Stehr M, Oehlmann W, Singh M, (2009) The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: development of a novel assay and quantification of glycolipid-status of the mycobacterial cell wall. J Microbiol Methods 79: 358-363.
7. Romano M, Huygen K, (2012) An update on vaccines for tuberculosis- there is more to it than just waning of BCG efficacy with time. Expert Opin Biol Ther 12: 1601-1610.
8. Lu D, Hickey AJ, (2007) Pulmonary vaccine delivery. Expert Rev Vaccines 6: 213-226.
9. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL, (2008) Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 8: 142-152.
10. Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, et al. (2007) The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122: 316-325.
11. Todoroff J, Ucakar B, Inglese M, Vandermarliere S, Fillee C, et al. (2012) Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. European Journal of Pharmaceutics and Biopharmaceutics doi: 10.1016/j.ejpb.2012.11.020.
12. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT, (2000) Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18: 2416-2425.
13. Fingerut E, Gutter B, Goldway M, Eliahoo D, Pitcovski J, (2006) B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet Immunol Immunopathol 112: 253-263.
14. Krieg AM, (2000) Immune effects and mechanisms of action of CpG motifs. Vaccine 19: 618-622.
15. Fischer G, Conceiçao F, Leite F, Moraes C, Ferreira L, et al. (2010) Recombinant Escherichia coli heat-labile enterotoxin B subunit humoral adjuvant effect depends on dose and administration route. World Journal of Microbiology and Biotechnology 26: 489-495.
16. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
17. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
18. da Hora VP, Conceicao FR, Dellagostin OA, Doolan DL, (2010) Non-toxic derivatives of LT as potent adjuvants. Vaccine 29: 1538-1544.
19. Barry M, Cooper C, (2007) Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 7: 1731-1737.
20. Casella CR, Mitchell TC, (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 3231-3240.
21. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, et al. (2006) Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80: 4962-4970.
22. Gartner T, Baeten M, Otieno S, Revets H, De Baetselier P, et al. (2007) Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. Immunol Lett 111: 26-35.
23. D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, et al. (2003) Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71: 483-493.
24. Grubhofer N, (1995) An adjuvant formulation based on N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with dimethyldioctadecylammonium chloride and zinc-L-proline complex as synergists. Immunol Lett 44: 19-24.
25. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, et al. (1999) Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67: 4586-4593.
26. Romano M, Roupie V, Wang XM, Denis O, Jurion F, et al. (2006) Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 118: 321-332.
27. Cooper AM, Torrado E, (2012) Protection versus pathology in tuberculosis: recent insights. Curr Opin Immunol 24: 431-437.
28. Nicod LP, (1999) Pulmonary defence mechanisms. Respiration 66: 2-11.
29. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M, (1996) Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 9: 1736-1742.
30. Boom WH, (1996) The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis 5: 73-81.
31. Ottenhoff TH, (2012) New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 20: 419-428.
32. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, et al. (2005) Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 174: 7986-7994.
33. Lemaire MM, Dumoutier L, Warnier G, Uyttenhove C, Van Snick J, et al. (2011) Dual TCR expression biases lung inflammation in DO11.10 transgenic mice and promotes neutrophilia via microbiota-induced Th17 differentiation. J Immunol 187: 3530-3537.
34. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
35. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
36. Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, et al. (2008) Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 105: 4656-4660.
37. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, et al. (2006) Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177: 6353-6360.
38. Jeyanathan M, Mu J, Kugathasan K, Zhang X, Damjanovic D, et al. (2008) Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung. J Immunol 181: 5618-5626.
39. Santosuosso M, McCormick S, Roediger E, Zhang X, Zganiacz A, et al. (2007) Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 178: 2387-2395.
40. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR Jr, Ernst JD, (2006) Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J Immunol 176: 3019-3027.
41. Sundaramurthy V, Pieters J, (2007) Interactions of pathogenic mycobacteria with host macrophages. Microbes Infect 9: 1671-1679.
42. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4: e6999.